The development of cancer is associated with gains and losses of DNA sequences throughout the genome. Array-based comparative genomic hybridization measures copy number variations at multiple loci simultaneously, providing an important tool for studying cancer and for developing diagnostic and therapeutic targets.
DNAVision provides you in collaboration with his parent institution (The Institute of Pathology and Genetics) with:
Agilent oligonucleotide arrays designed for CGH provide a robust and precise platform for detecting chromosomal alterations throughout a genome with high sensitivity using full complexity genomic samples
We provide services on the available CGH array from Agilent:
Genomic variations include both gains and losses of chromosomal regions that often vary extensively in their sizes.
The enhanced detection resolution enabled through the high-density microarrays delivers the highest precision in mapping chromosome breakpoints
and identification of micro-variations that are not detected by other platforms.
Using the Agilent technology, DNAVision is able to perform custom array untill a resolution of 190 bp
Clients submit frozen or embedded tissues, purified genomic DNA or EDTA-preserved blood.
You can find a description of the protocols following these links :